Hospital
South Broward Hospital District
South Broward Hospital District was paid $14.98M by Medicaid between Jan 2018 and Dec 2024, across 195 billing codes. Its largest line is 99283, emergency room visit (moderate) — 24% of everything it billed.
33Billing provider infoSOUTH BROWARD HOSPITAL DISTRICT
PEMBROKE PINES, FL 33024
PEMBROKE PINES, FL 33024
33aNPI1063495836assigned 11/25/2005
33bProvider typeGeneral Acute Care Hospital
28Total paid$14.98M
24GClaims642,926
24DCodes billed195
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other General Acute Care Hospital providers in Florida
Rank by total paid#30 of 163
Median peer was paid$4.77M
This provider vs. median3.1×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 52,361 | $837K | |
| 2019 | 126,108 | $1.85M | |
| 2020 | 89,146 | $1.41M | |
| 2021 | 115,413 | $2.85M | |
| 2022 | 136,022 | $3.45M | |
| 2023 | 84,171 | $3.02M | |
| 2024incomplete | 39,705 | $1.55M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 24% | 46,276 | 41,206 | $3.63M |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 21% | 36,617 | 31,239 | $3.07M |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 12% | 24,006 | 21,749 | $1.83M |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | 6.6% | 12,086 | 10,976 | $986K |
| 96361 | Intravenous infusion, hydration; each additional hour | 3.7% | 8,086 | 6,942 | $557K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 3.1% | 3,000 | 2,547 | $470K |
| 99214 | Doctor's office visit, returning patient (more involved)Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity | 2.2% | 12,957 | 8,487 | $324K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | 2.2% | 6,615 | 5,983 | $324K |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 2.1% | 5,994 | 4,760 | $319K |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | 1.3% | 4,718 | 4,326 | $193K |
| 70450 | Computed tomography, head or brain; without contrast material | 1.3% | 2,899 | 2,281 | $193K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | 1.0% | 1,232 | 1,033 | $151K |
183 more codes
| 80053 | Comprehensive metabolic panel | <1% | 26,645 | $146K |
| 36415 | Collection of venous blood by venipuncture | <1% | 31,030 | $142K |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | <1% | 6,666 | $139K |
| G0378 | Hospital observation service, per hour | <1% | 13,522 | $125K |
| 71275 | Computed tomographic angiography, chest, with contrast material | <1% | 879 | $121K |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 4,140 | $100K |
| 99215 | Doctor's office visit, returning patient (complex) | <1% | 1,812 | $98K |
| 82962 | <1% | 8,833 | $96K | |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | <1% | 4,115 | $88K |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 2,070 | $87K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 6,863 | $78K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 2,766 | $77K |
| 29580 | <1% | 1,584 | $76K | |
| 81025 | <1% | 13,963 | $73K | |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 5,050 | $71K |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 13,200 | $64K |
| 87631 | <1% | 1,022 | $58K | |
| 84702 | <1% | 11,528 | $55K | |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | <1% | 4,441 | $52K |
| 73130 | <1% | 1,247 | $50K | |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | <1% | 480 | $50K |
| 87088 | <1% | 6,634 | $49K | |
| 29581 | <1% | 600 | $44K | |
| 85027 | <1% | 4,733 | $44K | |
| 73562 | <1% | 1,728 | $43K | |
| 73630 | <1% | 1,608 | $43K | |
| 73610 | <1% | 1,211 | $43K | |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | <1% | 89 | $42K |
| 99213 | Doctor's office visit, returning patient (routine) | <1% | 3,064 | $40K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 14,256 | $38K |
| 86900 | <1% | 1,596 | $35K | |
| 71045 | Radiologic examination, chest; single view | <1% | 9,150 | $33K |
| 0241U | Neonatal screening for hereditary disorders, genomic sequence analysis panel | <1% | 6,614 | $32K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 36,210 | $32K |
| 87486 | <1% | 1,033 | $30K | |
| 84484 | <1% | 11,415 | $30K | |
| 87186 | <1% | 2,195 | $23K | |
| 81001 | <1% | 21,248 | $22K | |
| 81003 | <1% | 7,348 | $22K | |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 684 | $22K |
| 73110 | <1% | 597 | $20K | |
| 73030 | <1% | 1,000 | $19K | |
| 86850 | <1% | 976 | $17K | |
| 87633 | Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets | <1% | 1,059 | $15K |
| 83880 | <1% | 894 | $14K | |
| J2704 | Injection, propofol, 10 mg | <1% | 2,431 | $14K |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 8,825 | $13K |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 7,508 | $13K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 14,572 | $13K |
| 85610 | <1% | 5,510 | $12K | |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 1,948 | $12K |
| 10060 | <1% | 777 | $11K | |
| 85730 | <1% | 3,095 | $10K | |
| 83690 | <1% | 9,105 | $10K | |
| 45380 | Colonoscopy, flexible; with biopsy, single or multiple | <1% | 14 | $9K |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 1,637 | $9K |
| 73140 | <1% | 204 | $9K | |
| J0561 | Injection, penicillin g benzathine, 100,000 units | <1% | 87 | $9K |
| 76801 | <1% | 1,245 | $8K | |
| 99396 | Periodic comprehensive preventive medicine reevaluation, established patient, 40-64 years | <1% | 141 | $8K |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 1,958 | $7K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 8,806 | $7K |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 2,333 | $7K |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 547 | $7K |
| 70551 | Magnetic resonance imaging, brain; without contrast material | <1% | 57 | $6K |
| 93976 | <1% | 213 | $6K | |
| 87581 | <1% | 1,034 | $5K | |
| 87070 | <1% | 797 | $5K | |
| 87077 | <1% | 2,428 | $5K | |
| 80061 | Lipid panel | <1% | 2,184 | $5K |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 116 | $4K |
| 87040 | <1% | 1,418 | $4K | |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 4,597 | $4K |
| 93971 | <1% | 388 | $4K | |
| 94010 | <1% | 1,564 | $4K | |
| 85379 | <1% | 1,534 | $4K | |
| 94760 | <1% | 407 | $3K | |
| G1010 | Clinical decision support mechanism stanson, as defined by the medicare appropriate use criteria program | <1% | 4,170 | $3K |
| 74018 | <1% | 408 | $3K | |
| 87210 | <1% | 5,297 | $3K | |
| 76830 | Ultrasound, transvaginal | <1% | 405 | $3K |
| 12001 | <1% | 233 | $3K | |
| J1650 | Injection, enoxaparin sodium, 10 mg | <1% | 2,702 | $3K |
| J7512 | Prednisone, immediate release or delayed release, oral, 1 mg | <1% | 1,308 | $3K |
| 83735 | <1% | 2,091 | $3K | |
| 11042 | Debridement, subcutaneous tissue (includes epidermis, dermis, and subcutaneous tissue); first 20 sq cm | <1% | 32 | $3K |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 2,397 | $2K |
| 86901 | <1% | 1,584 | $2K | |
| 76817 | Ultrasound, pregnant uterus, real time with image documentation, transvaginal | <1% | 991 | $2K |
| 90715 | <1% | 1,172 | $2K | |
| 93970 | <1% | 35 | $2K | |
| Q0243 | Injection, casirivimab and imdevimab, 2400 mg | <1% | 85 | $2K |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 2,821 | $2K |
| 17250 | <1% | 160 | $2K | |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 351 | $2K |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 611 | $2K |
| 87205 | <1% | 814 | $2K | |
| 72100 | <1% | 270 | $2K | |
| 80076 | <1% | 685 | $2K | |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 2,955 | $1K |
| 94668 | <1% | 117 | $1K | |
| 88304 | <1% | 99 | $1K | |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 1,835 | $1K |
| 12011 | <1% | 105 | $1K | |
| 73080 | <1% | 62 | $1K | |
| 83605 | <1% | 1,271 | $1K | |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 909 | $1K |
| J2543 | Injection, piperacillin sodium/tazobactam sodium, 1 gram/0.125 grams (1.125 grams) | <1% | 1,218 | $1K |
| 74021 | <1% | 170 | $1K | |
| 94667 | <1% | 64 | $1K | |
| 86403 | <1% | 93 | $1K | |
| J0360 | Injection, hydralazine hcl, up to 20 mg | <1% | 266 | $1K |
| 87636 | Infectious agent detection by nucleic acid; SARS-CoV-2 and influenza virus types A and B | <1% | 1,929 | $1K |
| 29125 | <1% | 496 | $958.56 | |
| 82550 | <1% | 1,047 | $922.47 | |
| 70486 | <1% | 14 | $891.36 | |
| 29530 | <1% | 55 | $888.01 | |
| J2360 | Injection, orphenadrine citrate, up to 60 mg | <1% | 958 | $852.08 |
| 73590 | <1% | 15 | $733.70 | |
| 99395 | Periodic comprehensive preventive medicine reevaluation, established patient, 18-39 years | <1% | 22 | $722.16 |
| 73502 | <1% | 159 | $682.49 | |
| 86140 | <1% | 255 | $651.33 | |
| 29130 | <1% | 214 | $644.60 | |
| 85651 | <1% | 444 | $626.83 | |
| G1004 | Clinical decision support mechanism national decision support company, as defined by the medicare appropriate use criteria program | <1% | 917 | $626.04 |
| 74019 | <1% | 170 | $609.77 | |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 234 | $589.73 |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 4,668 | $449.70 |
| J2060 | Injection, lorazepam, 2 mg | <1% | 576 | $446.74 |
| 94762 | <1% | 36 | $410.32 | |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | <1% | 1,415 | $406.78 |
| M0243 | Intravenous infusion or subcutaneous injection, casirivimab and imdevimab includes infusion or injection, and post administration monitoring | <1% | 135 | $389.57 |
| 87184 | <1% | 43 | $226.30 | |
| 84439 | <1% | 198 | $210.80 | |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 77 | $206.68 |
| 88342 | <1% | 140 | $192.64 | |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | <1% | 57 | $191.08 |
| J0780 | Injection, prochlorperazine, up to 10 mg | <1% | 163 | $182.30 |
| 87075 | <1% | 114 | $173.20 | |
| J8540 | Dexamethasone, oral, 0.25 mg | <1% | 261 | $86.96 |
| 82728 | <1% | 34 | $78.86 | |
| 96376 | <1% | 168 | $78.46 | |
| U0001 | Cdc 2019 novel coronavirus (2019-ncov) real-time rt-pcr diagnostic panel | <1% | 27 | $60.00 |
| 84100 | <1% | 92 | $59.26 | |
| 3044F | <1% | 784 | $40.00 | |
| 72040 | <1% | 56 | $38.61 | |
| 87081 | <1% | 105 | $23.41 | |
| 99406 | <1% | 16 | $21.71 | |
| 84145 | <1% | 20 | $16.14 | |
| 83540 | <1% | 28 | $7.81 | |
| J3370 | Injection, vancomycin hcl, 500 mg | <1% | 30 | $7.59 |
| 3725F | 0% | 9,697 | $0.00 | |
| 1160F | 0% | 198 | $0.00 | |
| 3078F | 0% | 2,067 | $0.00 | |
| J7510 | Prednisolone oral, per 5 mg | 0% | 477 | $0.00 |
| 36600 | 0% | 15 | $0.00 | |
| Q9957 | Injection, perflutren lipid microspheres, per ml | 0% | 18 | $0.00 |
| G2211 | Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's single, serious condition or a complex condition. (add-on code, list separately in addition to office/outpatient evaluation and management visit, new or established) | 0% | 34 | $0.00 |
| 82570 | 0% | 60 | $0.00 | |
| 82272 | 0% | 15 | $0.00 | |
| 1159F | 0% | 213 | $0.00 | |
| J2272 | Injection, morphine sulfate (fresenius kabi), not therapeutically equivalent to j2270, up to 10 mg | 0% | 12 | $0.00 |
| 00731 | 0% | 91 | $0.00 | |
| 29515 | 0% | 41 | $0.00 | |
| C9113 | Injection, pantoprazole sodium, per vial | 0% | 158 | $0.00 |
| M0239 | Intravenous infusion, bamlanivimab-xxxx, includes infusion and post administration monitoring | 0% | 22 | $0.00 |
| 99080 | 0% | 30 | $0.00 | |
| 99499 | 0% | 18 | $0.00 | |
| 3008F | 0% | 5,795 | $0.00 | |
| 1126F | 0% | 3,676 | $0.00 | |
| 3351F | 0% | 6,493 | $0.00 | |
| G8510 | Screening for depression is documented as negative, a follow-up plan is not required | 0% | 7,817 | $0.00 |
| 3074F | 0% | 1,085 | $0.00 | |
| 1170F | 0% | 495 | $0.00 | |
| 29540 | 0% | 55 | $0.00 | |
| 1125F | 0% | 272 | $0.00 | |
| 1111F | 0% | 205 | $0.00 | |
| 73090 | 0% | 13 | $0.00 | |
| 83615 | 0% | 32 | $0.00 | |
| 3017F | 0% | 35 | $0.00 | |
| 87340 | 0% | 17 | $0.00 | |
| J1940 | Injection, furosemide, up to 20 mg | 0% | 31 | $0.00 |
| 1123F | 0% | 17 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialBURNS, MELISSA (DIRECTOR)
| Provider | Location | Paid |
|---|---|---|
| South Broward Hospital District | Hollywood, FL | $81.73M |
| South Broward Hospital District | Pembroke Pines, FL | $22.75M |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.